Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
S. Y. Barbour
Consultant or Advisory Role - Eisai
G. R. Morrow
No relevant relationships to disclose
R. Ahmed
Employment or Leadership Position - Eisai
G. Ballinari
No relevant relationships to disclose
M. D. Thorn
Consultant or Advisory Role - Helsinn Therapeutics
D. Cox
Employment or Leadership Position - Eisai
L. S. Schwartzberg
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai